Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Unternehmen & Branche
| Name | X4 Pharmaceuticals, Inc |
|---|---|
| Ticker | XFOR |
| CIK | 0001501697 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 47,0 Mio. USD |
| Beta | 0,33 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 6,500,000 | -79,199,000 | -1.87 | 290,461,000 | 186,290,000 |
| 2025-09-30 | 10-Q | 1,566,000 | -29,815,000 | -0.69 | 163,555,000 | 61,619,000 |
| 2025-06-30 | 10-Q | 1,744,000 | -25,741,000 | -3.47 | 105,168,000 | 3,971,000 |
| 2025-03-31 | 10-Q | 900,000 | 282,000 | 0.04 | 130,013,000 | 22,944,000 |
| 2024-12-31 | 10-K | 2,600,000 | -37,450,000 | -5.59 | 146,447,000 | 22,149,000 |
| 2024-09-30 | 10-Q | 560,000 | -36,696,000 | -5.48 | 178,165,000 | 59,621,000 |
| 2024-06-30 | 10-Q | 563,000 | 90,833,000 | 13.57 | 210,611,000 | 94,451,000 |
| 2024-03-31 | 10-Q | 0 | -51,766,000 | -7.77 | 112,182,000 | 1,036,000 |
| 2023-12-31 | 10-K | 0 | -101,167,000 | -17.07 | 147,258,000 | 51,099,000 |
| 2023-09-30 | 10-Q | 0 | -2,305,000 | -0.01 | 173,293,000 | 67,594,000 |
| 2023-06-30 | 10-Q | 0 | -55,712,000 | -0.33 | 173,399,000 | 67,535,000 |
| 2023-03-31 | 10-Q | -24,020,000 | -0.16 | 124,405,000 | 51,676,000 | |
| 2022-12-31 | 10-K | 0 | -93,867,000 | -1.52 | 155,586,000 | 74,051,000 |
| 2022-09-30 | 10-Q | -21,586,000 | -0.26 | 113,406,000 | 61,849,000 | |
| 2022-06-30 | 10-Q | -21,212,000 | -0.60 | 81,019,000 | 30,073,000 | |
| 2022-03-31 | 10-Q | -21,965,000 | -0.72 | 99,625,000 | 49,714,000 | |
| 2021-12-31 | 10-K | 0 | -88,696,000 | -3.99 | 117,176,000 | 64,412,000 |
| 2021-09-30 | 10-Q | 0 | -20,175,000 | -0.76 | 120,517,000 | 68,679,000 |
| 2021-06-30 | 10-Q | 0 | -19,638,000 | 141,659,000 | 87,338,000 | |
| 2021-03-31 | 10-Q | 0 | -18,676,000 | 161,035,000 | 105,062,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-23 | Craig Adam R | Director, Officer, Executive Chairman | Open Market Purchase | 86,206 | 2.90 | 249,997.40 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.